Technology Listings


Asparagine Endopeptidase (Legumain) Inhibitors for Treating Neurological Disorders

Application

Small molecule inhibitors of asparagine endopeptidase for the treatment of neurological disorders.

Key Benefits
  • Nontoxic and specific inhibitors selectively block asparagine endopeptidase (AEP), leaving other related cysteine proteases unaffected.
  • Alzheimer’s candidate is blood-brain barrier permeable.
Market Summary

Nearly 36 million people worldwide have Alzheimer’s disease or a related dementia and that number is expected to rise as life expectancy and overall population continues to increase in the United States and around the world. Asparagine endopeptidase (AEP) is implicated in various human disorders including cancers and neurodegenerative diseases. AEP is upregulated in aged normal brain and human Alzheimer’s disease (AD) brain. Several inhibitors of AEP have been described; however, they are all peptide-based, subject to proteolytic degradation and tend to exhibit low bioavailability. An effective small molecule inhibitor of AEP has yet to be identified and current therapeutics only treat symptoms and/or delay disease progression.

Technical Summary

Emory inventors have identified small-molecule inhibitors of asparagine endopeptidase (AEP). The lead compounds are cell permeable with low cytotoxicity and highly selective for AEP, reducing reactivity to other cysteine proteases. Chronic treatment of 5xFAD and TauP301S mice with oral administration of one lead compound ameliorates synapse loss and augments long-term potentiation (LTP), resulting in lower memory loss. This compound also exhibits high blood-brain barrier permeability. This lead compound is a great candidate to treat neurological disorders including Alzheimer’s disease. Another compound was shown to inhibit breast cancer cell migration.

Development Stage

Lead compounds have been characterized for their pharmacokinetics and toxicity and tested in mouse models.

Review our Breakfast Club PowerPoint

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Nationalized PCT - Foreign EP 15777056.1   9/15/2016    
Nationalized PCT - Foreign China 201580018484.5   10/8/2016    
Nationalized PCT - United States United States 15/303,458 10/11/2016    
Tech ID: 14046
Published: 10/25/2016
Category
Therapeutics

Contact
Cliff Michaels
Assistant Director
Emory University
404-727-3890
ccmicha@emory.edu

Inventor(s)
Keqiang Ye
Haian Fu
Yuhong Du

Keywords
Neuroscience/Pain
Small Molecule